Precision oncology through liquid biopsies involves the analysis of circulating tumor DNA (ctDNA) found in a patient's blood. This method allows for non-invasive monitoring of cancer progression and response to treatment.
Traditional biopsies are invasive and may not capture all tumor cells. Liquid biopsies provide a less invasive alternative for ongoing monitoring, enabling early detection of cancer recurrence or treatment resistance.
Samples of blood are collected from patients, which contain fragments of ctDNA shed by tumors. Advanced sequencing technologies identify specific genetic mutations present in the ctDNA. These data can be used to tailor treatments based on the unique characteristics of the patient's tumor.
The manufacturing process involves developing highly sensitive sequencing technologies capable of detecting low concentrations of ctDNA in complex blood samples. This requires advanced bioinformatics tools to accurately interpret the data.
Building a liquid biopsy system includes developing sample collection kits, designing microfluidic devices for DNA extraction and purification, integrating high-throughput sequencing platforms, and creating software algorithms to analyze the genetic information.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.